Skip to main content
IONIS PHARMACEUTICALS INC logo

IONIS PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · IONS ISIN · US4622221004 LEI · 549300SI4ZGLG0BLUZ92 US Manufacturing
Open in API
Filings indexed 1,796 across all filing types
Latest filing 2023-05-23 Regulatory Filings
Country US United States of America
Listing US IONS

About IONIS PHARMACEUTICALS INC

https://www.ionis.com/

Ionis Pharmaceuticals, Inc. is a biopharmaceutical company that discovers and develops RNA- and DNA-targeted therapeutics. Leveraging its expertise in antisense technology and a deep understanding of genetics, the company creates novel medicines designed to treat a wide range of serious diseases. Its development pipeline and marketed products primarily address neurologic and cardiometabolic disorders, as well as other areas with high unmet patient needs, including rare diseases. The company's approach aims to provide new solutions for complex and often intractable conditions by targeting the root cause of disease at the genetic level.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings
2023-05-23 English
Regulatory Filings 2023
Regulatory Filings
2023-05-22 English
IONIS PHARMACEUTICALS INC 10-Q 3-31-2023
Interim / Quarterly Report Q1 2023
2023-05-03 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 3, 2023, reporting the company's financial results for the quarter ended March 31, 2023. It includes a press release announcing quarterly financial results, which is typical of an Earnings Release. The document explicitly states it is a Current Report on Form 8-K and includes a press release as an exhibit. The length is 4033 characters, which is relatively short and consistent with an earnings release announcement rather than a full interim report. The content focuses on results of operations and financial condition for a quarter, which aligns with an Earnings Release (ER) rather than a full Interim/Quarterly Report (IR) that would contain detailed financial statements. Therefore, the appropriate classification is Earnings Release (ER).
2023-05-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used to announce unscheduled material events or corporate changes. The content describes an announcement of FDA approval of a drug by the company's partner, and includes a press release as an exhibit. There are no financial statements or detailed financial data presented. The document is short (3033 characters) and primarily serves as a regulatory announcement of an event rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2023-04-25 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The content describes a press release about positive Phase 3 clinical trial results and their presentation at a scientific meeting. There are no financial statements or detailed financial data included, and the document length is only 3162 characters, indicating it is a brief announcement rather than a full report. The document also references an attached press release as an exhibit. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement reporting a material event but not a full financial report or earnings release.
2023-04-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.